National Biotechnology Research Park

No. 99, Ln. 130, Sec. 1, Academia Rd.,
Nangang Dist., Taipei City 11571, Taiwan (R.O.C.)
Tel: +886-2-7750-5500
https://nbrp.sinica.edu.tw/

Biomedical Translation Research Center (Administrative Affairs)

Tel: +886-2-7750-5500 #1421
https://biotrec.sinica.edu.tw/

Innovation Incubation Center (BioHub Taiwan)

Tel: +886-2-7750-5500 #3147

BioTReC

NBRP

No.1 December.2022

NATIONAL BIOTECHNOLOGY RESEARCH PARK

INVESTMENT DIRECTORY AND RESOURCES IN BIOMEDICAL ECOSYSTEM



INVESTMENT DIRECTORY AND RESOURCES

National
Biotechnoloy
Research
Park

Table Of Contents

ABOUT NBRP

To stimulate and promote valuable and effective biotechnology research, Academia Sinica in concordance with governmental development policy, has constructed the National Biotechnology Research Park (NBRP) in Nangang, Taipei; opened in October 2018.

NBRP not only aspires to be Taiwan's premier state-of-the-art biotechnology research park but also embraces the obligation to maintain natural environment. It is hoped that NBRP can serve as a model for innovative research and development, while upholding high standards for ecological preservation.



INSIGHT & MISSION

NBRP is the 1st biomedical research park established in Taiwan. It aims to accelerate the development timelines for new drugs serving unmet medical needs, with the ultimate goal of enhancing human health and welfare.

As a coherent engine driving pharmaceutical research and development, NBRP has built a bio-corridor for academic research and pharma R&D to maximize the efficiency across value chains. NBRP focuses on the first part of journey toward biotechnological success by creating strong links between basic research and pre-clinical studies. Pre-clinical research results are then led to further product development and mass production.

NBRP ECOSYSTEM

NBRP serves as a single enterprise and plays a pivotal role in facilitating innovative research by closely integrating the resources of four government institutions to create an efficient cluster effect. These institutions include the Biomedical Translation Research Center of Academia Sinica (BioTReC), the Development Center for Biotechnology of Ministry of Economic Affairs (DCB), the National Applied Research Laboratories National Laboratory Animal Center of National Science and Technology Council (NLAC), and the Taiwan Food and Drug Administration of Ministry of Health and Welfare (TFDA).

Biomedical Translation Research Center, Academia Sinica

- Support innovative biomedical translation research
- Assist with technology transfer of R&D results
- Incubate startup companies
- Provide state-of-the-art core facilities and international level research talents

Development Center for Biotechnology, Ministry of Economic Affairs

- Specialize in the preclinical development of new drugs and provide translational value-added services
- Provide service and assessments for projectsourcing, technology licensing, startup incubation, and commercialization consulting

National Laboratory Animal Center National Applied Research Laboratories, National Science and Technology Council

- Provide diversified animal resources and testing services
- Fulfill the needs of biomedical product development and medical research
- Accelerate the internationalization of biotechnology industry

Taiwan Food and Drug Administration, Ministry of Health and Welfare

- Provide counseling and legal consultation services for biomedical industry
- Strengthen the competitive advantages of biomedical products and intensify integration of biotechnology development activities

Biomedical Translation Research Center

The Biomedical Translation Research Center (BioTReC) was founded in September 2019 at the National Biotechnology Research Park with the aspiration to support the development of biotechnology in Taiwan. The objectives of BioTReC align with government initiatives to accelerate bio-entrepreneurship from early discovery stages to commercialization.

The center consists of four divisions, including the Translational Medicine Division (TMeD) Innovation Incubation Center (BioHub Taiwan), Smart Medicine Division (SMeD), and Emerging Infectious Disease Division (EIDD). The establishment of BioTReC aims to forge a professional and innovative ecosystem that facilitates new drug discovery, as creation of a thriving biotechnology industry will ultimately enhance human health and welfare.

01 Translational Medicine Division *(TMeD)*

To enhance the international competitiveness of new drug development and medical applications from translational research to clinical use, TMeD placed strong focus in facilitating industry-oriented innovation and multi-disciplinary collaboration in translational medicine. In addition, TMeD provides resident companies and domestic researchers in academia, research, and industry with advanced instruments, equipment, and technical services for translational research on disease prevention, detection, diagnosis, and treatment.

02 Innovation Incubation Center *(BioHub Taiwan)*

BioHub Taiwan consolidates resources and provides one-stop service to support resident companies during R&D stage and subsequent product commercialization with the mission to foster the growth of domestic startups and entrepreneurs. BioHub Taiwan is committed in building an innova- tive biomedical ecosystem by bridging domestic / foreign R&D technologies and resources to promote development of innovative biomedical ecosystems. BioHub Taiwan also places strong emphasis in integrating interdisciplinary knowledge and skill sets into the NBRP Academy to cultivate business talents and provide business mentorship to bridge the gap between fundamental research and industrial applications.

03 Emerging Infectious Disease Division *(EIDD)*

EIDD was established with the mission to pre-deploy and reserve R&D capacities to immediately respond to outbreaks of emerging infectious diseas- es. Besides providing P2 and P3 facility services and rapidly develops identification/rapid testing technol- ogies and therapeutic antibodies, drugs, and vaccines, as well as next-generation technologies to fight against serious infectious diseases; EIDD also collaborates with relevant units in industry, govern- ment, academia, and research that help to build up a comprehensive strategy for the prevention and treatment of critical infectious diseases.

04 Smart Medicine Division *(SMeD)*

SMeD aims to help accelerate the R&D of big data technology transfer in the smart healthcare sector, to advance precision medicine development, and to build an industry ecosystem to improve overall social interest. SMeD will integrate the Taiwan Biobank Project, Taiwan Precision Medicine Initiative (TPMI), Cancer Moonshot Project of Academia Sinica, and other relevant big data in biomedicine, and it will also establish a big data center.

Best-in-class Core Facilities

01 Medicinal Chemistry and Analytical Core Facility

02 Taiwan Mouse Clinic

03 Core Facilities for Translational Medicine

04 RNA Technology Platform and Gene Manipulation Core

05 Taiwan Biobank

06 Human Therapeutic Antibody Development Platform

07 Infectious Diseases Core Facility

08 Animal Imaging Facility

09 Nucleic Acid Pilot (*Under Planning)

BioHub Taiwan

With the aspiration to support the development of biotechnology in Taiwan, BioHub Taiwan @NBRP was opened in Oct. 2018, in collaboration with different ministries in NBRP, to promote impactful fundamental research into commercialization. The Innovation Incubation Center of BioTReC, Academia Sinica was established in Sep. 2019 to coordinate and execute the mission of BioHub Taiwan.



One-stop Service for Startups

BioHub Taiwan aims to consolidate resources among different ministries, academics, and industries to provides one-stop service to support resident companies during R&D stage and subsequent product commercialization. With the mission to foster the growth of domestic startups and entrepreneurs, BioHub Taiwan is committed in building and promoting the development of innovative biomedical ecosystem by bridging domestic / foreign R&D technologies and resources. Its strategic focus yields the formation of new hotspot for biomedical industry as well as investment in Taiwan and the Asia-Pacific region.

Resident Start-ups & Companies in NBRP

AcadeMab Biomedical, Ascendo Biotechnology, AIBIOS K.K., CHO Pharma, Immunwork, OBI Pharma, Oneness, PapiVax, Pharmaessentia, Vacino Biomed, ZHENG YANG BIOMEDICAL, Zenith BioDesign Lab

Anbogen Therapeutics, AnHorn Medicines, ALPS Biotech, Agari Pharma, Excelsior Biopharma, Exland Biotechnology, Foresee Pharmaceuticals, Pharmasaga, SINEW PHARMA, Saint Therapeutics, Win Lux Biotech, *The One Biopharmaceutical

Acer, Bio Preventive Medicine, Horuseye Technology, i Analyzer Incorporation, JUN ZHI Biomedical, Instant NanoBiosensors, LumiSTAR Biotechnology, LuminX Biotech, Molsentech, Nebulum Technologies, NanoRay, SYNCELL, VITAE Biomedical

Advanced Connection Technology, Apexcella Biomedical, DrSignal BioTechnology, MELLO BIOTECH TAIWAN, Ochre Bio Taiwan, Polaris Biopharmaceuticals, ROCK BIOMEDICAL, Topmunnity, * Elite BioPharma, *SMOBIO Technology

BMCC, Taiwan BIO, VMIC, (*non-commercial service providers)

Contract review in process
Data as of 2nd September 2022

NBRP Academy

To foster an entrepreneurial mindset and develop business skills for biotech start-ups, BioHub Taiwan places strong emphasis in integrating interdisciplinary knowledge and skill sets to facilitate establishment of NBRP Academy. With the aim of helping biotech talents succeed at different phases and stages, it consolidates the resources from the cooperative partner at NBRP. These institutions include the BioTReC of Academia Sinica, the DCB of Ministry of Economic Affairs, the Center for Drug Evaluation (CDE), the NLAC of National Science and Technology Council, Biotech Industrial Academy (BIA), and Amgen Taiwan.

NBRP Academy not only aims to cultivate business talents by constructing the training program on scientific innovation and entrepreneurship, but it also provides consultation services and guidance for startups to bridge the gap between fundamental research and industrial applications.

- **Core curriculum**
  - Business Plan workshop – Industry, Venture Capital & Accounting Firm Experts in Taiwan
  - IP & Market analysis workshop - Cortellis and Derwent Innovation
  - Clinical Research Protocol workshop - Taiwan FDA & Center for Drug Evaluation
- **Entrepreneurship counseling**
  - Entrepreneurship Workshops - Industry Experts
  - Bio-Startup Seminar - Consultor &Industry Experts
- **Experience sharing with successful entrepreneurs**
  - International link & Professional mentoring - Industry Experts

BioHub Taiwan Accelerator

BioHub Taiwan Accelerator was found with the aim of building a competitive ecosystem for the biotech industry in Taiwan. It integrates resources among different academic, private, public and research sectors to assist with commercializing biotech discoveries and facilitating the growth and expansion of collaborations with innovative biotech companies.

It has partners coming from venture capital (VC), law firms, international pharmaceutical companies, and incubators; This innovative biomedical ecosystem can generate positive communication environment, by sharing resources and experiences, more companies can replicate the success model and create a win-win solution.

NBRP BioHub Taiwan

Investment Opportunities

Resident Companies

Biologics

1

INVESTMENT OPPORTUNITIES

RESIDENT COMPANIES →

Ascendo Biotechnology, Inc.
先知生物科技股份有限公司

COMPANY DESCRIPTION

Ascendo Biotechnology, Inc. (“ASCENDO”) is an innovative biotech Cayman-registered company originated from Taiwan. The Company’s mission is to develop cutting-edge approaches to revive the immunological momentum for patients with cancer and chronic viral infection to provide an opportunity to cure their diseases.

BUSINESS DESCRIPTION

ASCENDO focuses on the development of a first-in-the-class innate immune checkpoint inhibitor and vaccines derived from a very versatile platform from bench to bedside. The exit strategies include out-licensing, partnership, and M&A.

TECHNOLOGY PLATFORM / PRODUCT

•ASD141

- First-in-the-class innate immune checkpoint inhibitor
- Break the bottleneck of current cancer immunotherapy through preventing a novel regulatory ligand from binding to a common regulator of PRR pathways
- Significantly enrich the infiltration of functional APCs and neoantigen specific cytotoxic T in TME
- Very synergetic with approved effector cell level of immune checkpoint inhibitors such as anti PD1/ PDL1 or CTLA4 in animal models
- Can dramatically ameliorate the acute injection reactions when in combination with anti-CTLA4 in animal models
- Very good tolerability in animal pharmacology and PK studies
- Current stage: Preclinical development and plan to submit IND in one year.

•NanoCherub®

- A versatile Electro-Kinetic nanocomplex antigen adjuvant & delivery platform for therapeutic vaccine and preventive vaccine development

•ASD253

- Therapeutic vaccine for hepatitis B that can achieve hepatitis B Surface antigen seroconversion in 100% of test animals of both HDI mice model and AAV model.
- No liver function abnormality was observed in all the animals tested in HDI mice and AAV mice model.
- Current stage: pre-clinical testing

•ASD254

- RBD based subunit protein preventive vaccine of Covid-19
- Non-polarized Th1/Th2 immunogenicity
- Very long lasting protection and clean GLP toxicity data.

Contact us

Chairman: Dr. Yen-Ta Lu
Contact Person: Teresa Chou

- +886-2-7728-8922
- Teresa.chou@ascendobiotech.com
- http://www.Ascendobiotech.com

AcadeMab Biomedical Inc.
研生生醫股份有限公司

Founded in 2020, AcadeMab Biomedical Inc. is a start-up company dedicated to the development of new antibody drugs in the medical field that requires urgent breakthroughs. As cancer is widely acknowledged as a leading cause of death across the globe, we take it upon ourselves to research on the cancer therapy as our first step. From there, we expanded to other life-threaten diseases in different fields. To this end, we have developed multiple in-house technology platforms to break fresh ground for new antibody drugs. Our mission is to improve life quality and human health by providing the first-in-class or best-in-class new antibody drugs.

With rapid breakthrough of biotechnology, drugs for cancer treatment have improved dramatically, evolving from small-molecule drugs to protein/antibody-based drugs, including antibody-drug conjugates (ADC) and CAR-T therapy. Having proprietary platforms and unparalleled technologies for the development of antibody, it can support the company’s sustainability on new product pipeline, and/or to support our partners moving forward via services provided.

With comprehensive patent portfolio deployment, AcadeMab continues to reinforce core capabilities for the R&D of antibody drugs to clinical. We are committed to the development of potential therapeutic antibody drugs, boosting our competitiveness, improving human health and wellbeing, and promoting the antibody derived biologics through global collaboration.

Contact us

Chairman: Juz-Hsiang Chiu
Contact Person: Pearl Fong, Chief Strategy Officer

- +886-2-2789-1212
- pearl.fong@academab.com
- https://www.academab.com/
- Rm. 724, Bldg. C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei City 11571, Taiwan (R.O.C.)

CHO PHARMA, INC.
醣基生醫股份有限公司

CHO PHARMA INC. was founded in 2013. As a pioneer in innovative glycotechnology and carbohydrate new drug development, we are devoted in providing better solutions for severe human diseases. Our core expertise is in the field of glycoengineering and the development of vaccine and antibody against novel carbohydrate antigens. Several pipeline products, which cover indications for human cancer, infection disease and autoimmune disease, have been created through our proprietary technologies CHOptimax™ and the integrated anti-carbohydrate vaccine and antibody development platform. CHO-H01, our first product for human non-Hodgkin lymphoma, has been approved to conduct phase I/II clinical trials in both Taiwan and the US. More product candidates are expected to be launched for clinical trials in the near future. Another product, universal COVID-19 vaccine, is a new vaccine also designed by CHOptimax™.



Contact us

President: Chung-Yi Wu
Contact Person: Sammi Chou

- +886-2-2655-8059 #105
- sammi.chou@chopharma.com.tw
- https://www.chopharma.com/
- 7F, Bldg. C, No.99, Ln.130, Sec.1, Academia Rd., Nangang Dist., Taipei City, 115, Taiwan (R.O.C.)

Immunwork Inc.
免疫功坊股份有限公司

Immunwork, Inc. was founded in 2014. We focus on the research, development, and commercialization of novel drugs to fulfill unmet medical needs. Our drugs are created based on our proprietary technology platform for treating multiple types of cancer, diabetes, obesity, non-alcoholic steatohepatitis (NASH), pathological blood clots, and other selected severe clinical conditions. Our unique platform allows us to design and generate novel "T-E" drug molecules, which contain targeting (T) and effector (E) moieties. These designs would help to improve the efficacy and limit toxicity. The majority of our T-E drugs are based on "multi-arm linkers" and various "drug bundles". These drug candidates include antibody-drug conjugates (ADCs), antibody-radionuclide conjugates (ARCs), ultra-long-acting therapeutic peptides, and drugs in other modalities. Six of the drug candidates have been selected and progressed into the pre-clinical development stage. Meanwhile, we are looking forward to applying the multi-arm linker platform for designing additional novel drug candidates.



Contact us

CEO: Tse-Wen Chang ; VP of Research: Hsing-Mao Chu
Contact Person: Kun-Po Li, Manager of External Collaboration and Clinical Development

- +886-2-2651-2268
- Kunpo.li@immunwork.com
- http://www.immunwork.com
- Rm. 520, Bldg. C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei City 11571, Taiwan (R.O.C.)

OBI PHARMA, INC.
台灣浩鼎生技股份有限公司

Founded in 2002 as a 100% subsidiary of Optimer in Taiwan, OBI Pharma was publicly launched in 2012 and listed on the Taiwan Stock Exchange in 2015.

OBI Pharma has positioned itself as a new drug research and development company dedicated to developing innovative cancer therapies. Initially focusing on developing the Globo series of glycosphingolipids (Globo H, SSEA-4), OBI has transformed into a cancer pharmaceutical company with a diversified technology platform and multiple targets over the years. OBI aims to develop first-of-a-kind new cancer drugs and innovative therapies with novel therapeutic targets to meet the needs of patients who still lack effective medical treatments, improve their health and enhance their quality of life.

OBI's core competency lies in pioneering first-in-class new drugs. OBI has a complete Globo Series pipeline line, including active immunization (vaccines), passive immunotherapy (monoclonal antibodies), and conjugates of small molecule drugs with antibodies (ADCs); and also developing new drugs in the small molecule field, targeting cancers with high expression of Aldo-Keto reductase AKR1C3. In recent years, OBI has been actively developing new products targeting TROP2. In addition, OBI also has achieved good results in developing cell therapy and the COVID-19 vaccine with full potential for development.

Contact us

Chairman / CEO: Michael Chang
Contact Person: Ronny Chen

· +886-2-2655-8799
· rchen@obipharma.com
· https://www.obipharma.com/
· 19F., No. 3, Park St., Nangang Dist., Taipei City 11503, Taiwan (R.O.C.)

Oneness Biotech Co., Ltd.
合一生技股份有限公司

Oneness Biotech has been keen on employment training, new drug development and innovation of technology. Our pipelines cover Phases I, II, III, NDA and approval phases. With strong R&D team and capability for new drugs, we have set up raw material cultivation bases, API and finished dosage manufacturing plant according to GACP and PIC/S GMP standards for botanical drugs. The streamlined control ensures the effectiveness, safety, and consistency of our drug quality. Besides, we have developed antibody new drugs for severe asthma, atopic dermatitis, and other indications based on the established proprietary technologies including fully-human antibody library, a high-performance screening platform, a stable and high-yield antibody-producing cell line, and a cancer stem cell platform.

The first approved new drug: Fespixon® (for DFUs), a first-in-class macrophage-regulating topical new drug has been granted approval in Taiwan and Macao. It is also under NDA review by health authorities in China, South East Asian countries as well as India, and has been granted a Fast Track designation by the US FDA to accelerate the development for the US market. Oneness dedicates its R&D efforts to chronic dermatological and immunological disorders and has out-licensed its atopic dermatitis antibody new drug for US$ 530 million to the global medical dermatology leader, LEO Pharma A/S in 2020. Through licensing or co-development, Oneness can provide patients with cost-effective treatments and achieve our founding mission of "developing new drugs and caring for life".



Contact us

Chairman: Shan-Ney Huang
Contact Person: Nien-Yi Chen (Vice President)

· +886-2-2655-8098 #653
· nienyichen@onenessbio.com.tw
· https://www.onenessbio.com/en
· 11F., No. 236, Sec. 4, Xinyi Rd., Da'an Dist., Taipei City 10680, Taiwan (R.O.C.)

PharmaEssentia Corporation
藥華醫藥股份有限公司

PharmaEssentia

PharmaEssentia Corporation (TPEx: 6446) is a fully integrated biotech company based in Taiwan. The company engages in innovation, clinical development, production and manufacturing of new drugs, and global commercialization. PharmaEssentia utilized its self-developed PEG molecule and PEGylation technology platform to produce a long-acting protein drug with the advantages of prolonged efficacy time and the simplest compound. The innovative long-acting interferon P1101 (Ropeginterferon alfa-2b) was invented by PharmaEssentia. Since 2019, Ropeginterferon alfa-2b has been approved by the agencies for the treatment of Polycythemia Vera (PV) in European Union, Taiwan, Switzerland, Israel, South Korea. In 2021, Ropeginterferon alfa-2b was approved by US FDA for PV.

PharmaEssentia is currently conducting the multi-country and multi-center Phase III clinical trials of P1101 for the treatment of Essential Thrombocythemia (ET) globally. After completion of the Phase III trials, the company will submit new drug application (NDA) in various countries. The company's Taichung plant has completed commercial mass production and was GMP certified by Taiwan FDA, EMA, South Korea MFDS, and US FDA. In addition, the company's filled and finished plant was also GMP and GDP certified by Taiwan FDA.

Therapeutic Area	Candidate	Indication	Market	Preclinical	Early Phase	Pivotal	Regulatory	Approval	Partnership
Hematology	Ropeginterferon alfa-2b (P1101)	PV	EU, CH, IL						AOP ORPHAN
			TW, KR						
			US						
			JP, CN						
		ET	Global						
		Adult T-Cell Leukemia	JP, TW, CN						
	Next generations of P1101	MPN	Global						
Infectious Disease	P1101 + Entry inhibitor	HDV	US, EU, TW						
Dermatology	KX01	Psoriasis	TW, CN, MO SG, JP, KR						Athenex
	KX01	Actinic keratosis	TW, JP, KR						Athenex
Oncology	P1101 + anti PD-1	HCC	Global						
	PEG-IL2	Solid tumor	Global						
	PEG-Gamma	Solid tumor	Global						
	P1101 Combo	Solid tumors	Global						
	TCRT	Solid tumors	US, TW						Axis

Contact us

General Manager: Jack Hwang

- +886-2-2655-7688
- ir@pharmaessentia.com
- http://www.pharmaessentia.com
- Rm. 814, Bldg. C, No.99, Ln.130, Sec. 1, Academia Rd., Nangang Dist., Taipei City 11571, Taiwan (R.O.C.)

Vacino Biotech
法信諾生醫股份有限

VACINO

Established in July 2020, Vacino Biotech Co., Ltd. is committed to the development of nucleic acid drugs and vaccine products. With self-developed next-generation vaccine design AD tech technology, COVID-19 T-cell vaccines are put into practice to solve the short period neutralizing antibodies of B-cell vaccines with short protection. In addition, nucleic acid drug target delivery technology has been developed, which has been invested in the field of Alzheimer's treatment to increase the drug load of brain therapeutic drugs, and developed nucleic acid drugs with modular technology.

COVID-19 T-cell vaccine: Research and development of COVID-19 T-cell vaccine to produce T-cell protection against the world's major COVID-19 viruses, and through oral dosage forms, more people can get protection in the shortest possible time and build up herd immune protection. The vaccine does not require the use of adjuvants, achieves the best safety profile, and is suitable for the elderly and adolescents.

Nucleic acid drugs: Research and development of neural nucleic acid drugs to inhibit gene expression through miRNA to achieve the protective effect of brain function. Through targeted delivery technology, a new generation of nucleic acid drugs can easily increase the effective dose of drugs reaching the brain.

PRODUCT PIPELINE



Contact us

Chairman: Jia-Ming Chang
Contact Person: Jia-Ming Chang, President

- +886-937-074-938
- jiaming@vacinobiotech.com
- https://vacinobiotech.com
- Unit 418, Building C, No. 99, Lane 130, Academia Rd., Sec. 1, Nangang Dist. Taipei 11571 Taiwan

Zheng Yang Biomedical Technology Co., Ltd.
正揚生醫科技股份有限公司

正揚生醫科技股份有限公司
ZHENG YANG BIOMEDICAL TECHNOLOGY CO., LTD.

Nucleic Acid Drugs & Regenerative Medicine

Zheng Yang Biomedical Technology Co., Ltd. (ZYBT) is a new drug development company, dedicated to the research and development of Elate Ocular™ dry eye biologics and new drugs. ZYBT was established in 2015 with cooperation with professors from EMORY University (Cambium Medical Technology, LCC) on cell culture supplement (FDhPL) patented product manufacturing, development and global sales rights. ZYBT cooperates with Cambium to develop new dry eye drugs and owns the global rights to manufacture its active ingredients, Aurarix™. The cell culture supplement technology extends to the treatment on dry eye. In the fourth quarter of 2017, Cambium obtained FDA approval to perform Phase I/II clinical trials, and completed Phase I/II clinical trials in 2019. Its clinical indicators and output results are very positive, current plan is to enter Phase II/III clinical trial application.



Contact us

Chairman: Tseng Yu-Hung
Contact Person: Vio Huang, CEO

· +886-2-2999-0280
· vio@atcbiomed.com
· http://www.zybt.com.tw/
· Rm. 322, Bldg. C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei City 11571, Taiwan (R.O.C.)

Advanced Connection Technology Inc.
長盛科技股份有限公司

Advanced Connection Technology Inc. not only has accumulated years of medical research development experience, but also connect several resources to achieve regenerative medicine, precision medicine and digital health fields; ACTT has a high standard GTP laboratory, professional cell culture specialist, to provide a variety of regenerative medicine development; Next Generation Sequencing laboratory brings all kinds of precision medicine research and development;With our SMO in the hospital, can provide resources for clinical trials and assist building data base With plenty of research experience and high level of digital connection can lower the cost and shorten the development path. Create the perfect clinical research and development services with full resources.

Contact us

Contact Person: James Chang

- +886-0958-214-995
- james.chang@actt.co
- A233, Building A, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei City 11571, Taiwan (R.O.C.)

DrSignal BioTechnology Co., Ltd.
博訊生物科技股份有限公司

DrSignal BioTechnology Co., Ltd. is a biotech-company which leads the world in building an automated cell production line and providing CDMO services as our main business model. Current relevant companies are either manufacturers developing and selling automated machines, or those providing cell manufacture OEM services with conventional GTP laboratories. Instead, DrSignal aims at the integration and standardization of the automated cell production with AI-assisted optimization, with our expertise in the biomedicine, hardware, and artificial intelligence.

Contact us

Chairman: Frank Mi. M.D. Ph.D.
Contact Person: Chia-Yi, Hsu. Ph.D.

- +886-2-2653-9569
- cy.hsu@drsignal.org
- http://www.drsignal.com.tw/
- Rm. 330, Bldg. C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei City 11571, Taiwan (R.O.C.)

Mello Biotech
美洛生物科技股份有限公司

mello biotech
Innovative MicroRNA Therapeutic

Mello Biotech is a research company specializes in development and commercialization of microRNA and stem cell technologies. Based on patented proprietary technologies in microRNA and stem cells, Mello Biotech currently focuses on the development of microRNA precursor for cancer treatment. Based on technical and commercial viability, initial indication is targeting “4th stage NSCLC patients not eligible for target therapy or immunotherapy”. Current in-vivo study data demonstrates good efficacy and safety in orthotopic animal models. The company aims to validate efficacy and safety of treatment in human. Objectives include manufacturing, pre-clinical experiments, application for IND, and clinical trial phase I.

Target Market Condition

- NSCLC: ~600,000 new patients annually in Japan, Europe & US.
- Indication: 4th stage NSCLC patients not eligible for target therapy or immunotherapy,second line after chemotherapy.
- Poor survival with current treatments – PFS in months.
- Current treatments are costly, toxic, undesirable side effects, and limited in efficacy.

Key Advantages & Features

- Proven efficacy in animal study.
- Inherently Safe – Technology derived from stem cells, laboratory proven safe.
- Technically Feasible - Deliverable and stable with proprietary delivery technology.
- Commercially Feasible – Large patient population with urgent medical need and limited options.
- Unique MOA - Allows for combination therapy.
- Comprehensive IP Protection - global patents secured in fundamental technology, manufacturing & applications.



Contact us

CEO / Contact Person: David Wu

- +886-2-2789-3558
- info@mellobiotech.com
- http://www.mellobiotech.com
- Rm. 422, Bldg. C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei City 11571, Taiwan (R.O.C.)

Rock BioMedical, Inc.
磐石醫藥生技股份有限公司

磐石醫藥生技
Rock BioMedical, Inc.

Founded in 2021, Rock BioMedical, Inc. (Rock Bio) is a biopharmaceutical company seeking to combine both active immunization (eg vaccines) and passive immunization (eg antibodies) for the eradication of diseases based on our proprietary Glyco-engineered Universal Vaccine platform. The initial focus will be on the development of next generation COVID vaccine featuring the unique property of our glycan-depleted SARS-CoV-2 spike protein (SMG) to induce broad protection against immune evading variants. Built upon the same technology platform, the company’s pipeline also includes novel therapeutic antibody and universal flu vaccine candidates that together will revolutionize the way such common respiratory tract infection can be managed in the future.

The company is founded upon a set of core technologies licensed from Academia Sinica. It has an R&D base located in National Biotechnology Research Park in Nangang Taipei and a subsidiary in Boston Massachusetts USA to manage its global CRO activities for clinical development and international partnership.



Image provided by Ma Lab

Contact us

Chairman: Yuan-Teh Lee, MD
Contact Person: Jeng-Shin Lee, MD, PhD

- +886-2-2788-5808
- jslee@rockbiomedical.com.tw
- http://www.rockbiomedical.com.tw
- Rm. 301, Bldg. A, 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei City 11571, Taiwan

Polaris Group
北極星藥業集團

Polaris
Novel Drugs For Cancer

Small Molecule Drugs & Botanical Drugs

Polaris Group is a multinational biotechnology company focused on developing novel anti-cancer therapies. Leading the way to new and better cancer treatments. Our lead drug candidate, Pegargiminase (ADI-PEG 20), is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia and others.

Polaris Group is involved in every stage of the drug development process. Our family of companies harnesses structure-based drug design technology to create novel oncology therapies, conducts clinical studies at top-tier cancer centers worldwide and operates cGMP production facilities in Northern California and China. Polaris Group is a Biotechnology CDMO provider for early-stage drug development.

Polaris Group announces positive top-line results from phase 2/3 ATOMIC study in patients with Malignant Pleural Mesothelioma to assess ADI-PEG 20 with Pemetrexed and Cisplatin. Given these results, Polaris Group will proceed with regulatory submissions in the United States in 2023. In 2022, ADI-PEG 20 received fast track designation from the FDA.



Fig. 1 | Pegargiminase converts extracellular arginine into citrulline. Cancer cells are therefore blocked from receiving this external supply of important nutrient. ADI, arginine deiminase; ARG, arginase; ASL, argininosuccinate lyase; ASS1, argininosuccinate synthetase.

Contact us

Chairman: Howard Chen
Contact Person: Jack Chen, Executive Assistant to the President

· +886-2-2656-2727
· jackchen@polarispharma.com
· https://polarispharma.com
· Taiwan: 2F.-1, No. 298, Ruiguang Rd., Neihu Dist, Taipei, Taiwan
· USA: 10675 Sorrento Valley Road, San Diego, CA 92121, USA

3

Anbogen Therapeutics, INC.
安邦生技股份有限公司

Anbogen Therapeutics (ABT) is a clinical stage biotech founded in 2019, based in Taipei, Taiwan. We focus on developing first/best-in-class precision oncology medicines. We target cancer patients harboring clinically validated driver mutations where we believe the unmet therapeutic needs are. There are two clinical-stage assets, ABT-101 and ABT-301 (HDAC-inhibitor), and several early research programs (e.g. ABT-202, a KRAS inhibitor) under development. The lead compound, ABT-101, is an oral TKI that targets actionable driver mutation, HER2 exon20 insertions, in NSCLC. With strong scientific knowledge and extensive experience in medicinal chemistry, drug discovery and clinical development, we are devoted to make impact to patients with cancer.



Contact us

President: Dr. John, Tsu-An Hsu
Contact Person: Angus Wu, VP in Business Development

· +886-2-8979-8616
· angus.wu@anbogen.com
· No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei City 11571, Taiwan (R.O.C.)

ALPS Biotech Co., Ltd.
浩峰生物科技股份有限公司

Founded in 2017, ALPS Biotech is a new drug research and developing company, dedicated to study biological functions of protein and natural product. In the short term, ALPS focuses on IP's generation including the early stage disease biomarkers discovery for developing in vitro diagnostic device (IVD), and immune therapy on oncology, as well as a variety of professional biotechnology service, such as protein/natural products separation, purification and identification technology. UP to now ALPS has filed many patents covered early diagnosis, better treatment for good quality of patient's life. Currently ALPS Biotech is looking for interested biotech or big pharma to co-development the IP's also.

PRODUCT	TYPE	TARGET	DISEASE	STAGE	POTENTIAL MARKET (USD)
AL-121	Botanic drug	ACE-2	Anti- COVID-19	Pre-Clinical (In vitro hamster data)	5.6 billion
AL-126	NCE	NLRP3 Inflammasome	Huntington' s disease	Pre-Clinical (In vivo mouse data)	252 million
AL-101	Botanic drug	Novel mechanism	combine Radiation therapy	Pre-Clinical (In vivo mouse data)	2.9 billion
AL-102	Botanic drug	ACE protein	Anti- HBP	Pre-Clinical (In vivo testing)	13.5 billion
AL-801	mAb	GM2AP	Lung Cancer	Pre-Clinical	22.9 billion
AL-801DX	Diagnostic	GM2AP	Lung Cancer DX	Pre-Clinical (2nd stage)	3.64 billion

Contact us

Chairman: Chen, Shui-Tein
Contact Person: Johnson Yu

· +886-2-2788-7626
· johnson.yu@alps.com.tw
· http://alps.com.tw
· Rm. 624. No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei City 11571, Taiwan (R.O.C.)

Agari Pharma Co.
明辰生技股份有限公司

明辰 生技股份有限公司 AGARI PHARMA

The research team of Agari Phama consists of the experts from I-MEI FOODS CO., LTD and LOHAS BIOTECH DEVELOPMENT CORP. Base on the toxin and metal free agaricus blazei murill planted by unique AI-controlling planting approach, we further concentrated on developing botanical drugs from it.

Contact us

Chairman: 高志明
Contact Person: Kai Hsia, Ph.D.

· +886-2-2782-1211 #101
· hkay1008@gmail.com
· Rm. 602, Bldg. C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei City 11571,Taiwan (R.O.C.)

AnHorn Medicines Co., Ltd.
安宏生醫股份有限公司

安宏生醫 AnHorn Medicines

AnHorn Medicines is a drug discovery platform company with a strong pipeline, offering therapies that target and degrade disease-causing proteins. Our mission is to develop new class of **BIGPRO**® (Bi-functional liGand induced PROteolysis) drugs under the foundation of Targeted Protein Degradation (TPD), to address a broad range of life-threatening and life-impairing diseases.

We offer effective drug candidates and partner with world leading pharmaceutical companies to carry project into real-world studies. We leverage on AnHorn's proprietary **AIMCADD**®, an AI-enabled platform, to turn innovation into new therapeutics – new opportunities to target difficult-to-treat and drug resisting diseases.

AnHorn's Drug Development Strategy:
· Focus on discovering **BIGPRO**® new drugs
· Go beyond next generation of targeted protein degradation by developing novel E3 ligase and its ligand
· Expand unexplored therapeutic opportunity in undruggable targets
· Establish a multilayer patent protection framework for projects

Program	Target	Indication	Discovery	Preclinical	Clinical Trial
AH-001	**Androgen Receptor**	**Androgenetic Alopecia**	*Open for Partnering*		
AH-003	**Androgen Receptor**	**Prostate Cancer**	*Open for Partnering*		
AR-V7 Program		Prostate Cancer			
KRAS G12C/D/V, G13D Programs		KRAS-Mutated Cancers			
Undisclosed Target Programs		Lymphoma& Various Cancers			
Novel E3 Ligase Programs		Various Cancers			

Contact us

CEO: Dr. Chu-Chung Lin
Contact Person: Wendy Lin

· +886-2-2786-2568
· anhorn01@anhornmed.com
· http://www.anhornmed.com
· Rm 522, Bldg C, No. 99, Ln 130, Sec 1, Academia Rd., Nangang, Taipei, Taiwan (R.O.C)

Excelsior Biopharma Inc. / Excelsior Pharmatech Labs.
科懋生物科技股份有限公司 / 科進製藥科技股份有限公司

EXCELSIOR
Professionalism · Innovation · Excellence · Service

Excelsior group has been dedicated to specialty medicines and medical examinations in rare diseases for more than 2 decades. In 2016, Excelsior group established a TGF-beta research center and start up new drug development projects to screen new drug candidates of enhancers and inhibitors targeting at TGF-beta activities in various diseases, such as wound healing, cardiovascular diseases, autoimmune diseases, liver cirrhosis, pulmonary fibrosis, neurodegenerative diseases, and cancer treatments. In 2020, Excelsior group is expanding our team in the field of rare diseases and establish a new research center of specific diseases aim at genetic and metabolic disorders in National Biotechnology Research Park, NBRP. In NBRP, we are investing in precision medical testing, epidemiology study, new drug development, and novel therapeutic technologies in various rare diseases. Besides, we are also looking for more strategic alliances with Academia Sinica, National Health Research Institute and leading medical centers in Taiwan. Our aim is to establish a world-class laboratories in the research of TGF-beta and specific diseases and extend our services to Asian populations.

Selected Products	Indications	Status
EX042-002-05	Rare disease	Lead optimization
EX042-002-11	Rare cancer	Lead optimization
EX042-002-06	Tissue fibrosis	Prove of concept
EX042-004-09	Alzheimer's disease	Research

Contact us

President: Joseph Chen
Contact Person: Donna Tseng

- Donna.Tseng@excelsiorgroup.com.tw
- http://www.excelsiorgroup.com.tw/
- Rm. 622, Bldg. C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei City 11571, Taiwan (R.O.C.)

Exland Biotechnology Inc.
臺萃生技股份有限公司

臺萃生技股份有限公司
Exland Biotechnology Inc.

Exland biotechnology inc. manufactures, supplied, and exports functional plant extracts in Taiwan for the past 12 years. Our R&D team is staffed with the most experienced experts in traditional herbs and plants. We are proud to hold a multinational patent of our own extraction technology, Superdash® extraction, certified in Taiwan, USA, China, and Germany. Exland's Superdash® extraction technique yields the highest extraction efficiency resulting in higher concentration of active ingredients than our competitors. By utilizing water extraction, we are able to achieve zero organic solvent residues in our products, offering a healthier and higher quality choice to the market. Our mission strives towards the highest extraction excellence in functionality, taste, color and aroma. Given our background in medicine and nutrition, Exland has been ever invested in our R&D ability and close collaboration with our partners and clients to provide the best product for our consumers.



Contact us

President: Hsiu-yen Yen
Contact Person: Nan-Pin Kao

- +886-49-2259731 / +886-2-26558768
- +886-972-737-528
- npkao@exlandbio.com.tw
- http://www.exlandbio.com.tw/
- No. 26, Gongye E. Rd., Nantou City, Nantou County 540028, Taiwan (R.O.C.)
- Rm. C414, 4F., No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei City 115202, Taiwan (R.O.C.)

Foresee Pharmaceuticals Co., Ltd.
逸達生物科技股份有限公司

Foresee is a Taiwan and US-based biopharmaceutical company listed on Taipei Exchange（TPEx：6576）. Foresee's R&D activities consist of two areas, the proprietary stabilized injectable formulation (SIF) targeting specialty markets, and the first-in-class NCE programs targeting rare and severe diseases.

SIF technology：CAMCEVI® 42 mg (6-month depot injection formulation), indicated for the treatment of advanced prostate cancer, was the first commercial product developed from Foresee's SIF platform. CAMCEVI® 42 mg has been approved in the US, EU, Canada, and was launched in the US in April 2022.

NCE programs：FP-025, a first-in-class oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases currently in a Phase 2 proof-of-concept study in allergic asthma. FP-045, a first-in-class oral ALDH2 activator, is in a Phase 1b/2 for Fanconi Anemia.



Contact us

Chairman & CEO: Ph.D. Ben Chien
Contact Person: Max Chan - CFO

· +886-2-7750-0188
· ir@foreseepharma.com
· http://www.foreseepharma.com/en-us
· 9F-2., No.19-3, Sanchong Rd., Nangang Dist., Taipei City 115, Taiwan

SINEW PHARMA INC.
欣耀生醫股份有限公司

(The company currently develops six core products based on the two technology platforms of "Liver Metabolic Enzyme Activity" and "Gene Regulation". Two are for the treatment of non-alcoholic steatohepatitis (NASH), and three are new formulations and combo of hepatotoxicity-free painkiller Acetaminophen and one is an antidote for Acetaminophen poisoning.

New drugs for the treatment of NASH, of which SNP-610 has been approved by the US FDA and Taiwan's TFDA for Phase II clinical trials in May 2017, and is the first-in-class new drug in the market; SNP-630 is an optimized drug with a new ingredient NCE), a Phase I clinical trial is now underway.

Among the other three SNP-8 products, SNP-810 is a new non-hepatotoxic Acetaminophen analgesic drug, which has been approved for the US OTC monograph sales license and Taiwan's drug license. At the same time, it has applied for a US FDA pivotal trial. SNP-820 is an antidote for Acetaminophen poisoning and is applying for entry into clinical trials in Taiwan and the United States by way of application for orphan drugs. Compound SNP-830 and SNP-840 are patented new compound non-hepatotoxic analgesic drugs containing SNP-810 and analgesic and anesthetic ingredients. In the future, SNP-810 and non-addictive analgesics such as Sebacoyl Dinalbuphine Ester will be developed into new therapeutic effects. The new compound drug is currently undergoing preparations for clinical trials of the new compound new drug.



Contact us

Chairman / Chief Executive Officer: Kai-Min Chu, MD, Ph.D.
Contact Person: Tina Peng

· +886-2-2788-5365
· info@sinewpharma.com
· https://www.sinewpharma.com
· Rm. 516, Bldg. C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei City 11571, Taiwan (R.O.C.)

Saint Therapeutics LLC
聖德生技新藥有限公司

Saint Therapeutics (ST) is a clinical-stage biotechnology company focused on revolutionizing tissue repair and disrupting the billion-dollar scar reduction and chronic wound healing industries. Building upon over 20 years of research into how fetal skin heals rapidly and without scarring, ST is developing SLI-F06, a unique, patent-protected, first-in-class peptide drug to significantly reduce scar formation after surgery and to promote healing.

SLI-F06 has completed nonclinical efficacy and safety, human Phase 1, and preliminary Phase 2a studies of injectable liquid SLI-F06 for scar reduction during surgery. Both Phase 1 and 2a results show preliminary evidence of improvement in several individual POSAS parameters related to scarring on the SLI-F06 treated side in high tension.

The FMOD/SLI-F06 technology is also supported by 20 academic papers; $14M in NIH/SBIR grant awards; 16 patents granted in USA, Canada, UK, France, Germany, China, Korea, and Taiwan; and 10 pending patents in various countries.

Formulation	Indication	Discovery	Preclinical	Phase 1	Phase 2	Phase 3	NDA
Liquid SLI-F06 - Injectable	Acute (1st time) scar reduction				Lead		
	Preexisting scar revision surgery				Lead		
	Diabetic foot ulcer healing			Secondary			
Hydrogel SLI-F06 - Injectable - Implantable	Bioactive adjuvant to increase device (sutures, mesh) healing						
	Tissue healing (tendon)						
	Tissue healing (fascia, muscle)						
Topical SLI-F06	Diabetic foot ulcer healing						
	Burn injury						

Contact us

Chairman: Dr. Kang Ting, CEO
Contact Person: Amy Chen

· +886-2-2547-3685
· yychen1992@gabrielamc.com.tw
· Rm. 816, Bldg. C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei City , Taiwan

WinLux Biomedical Technology LTD.
穩茂生物醫藥科技股份有限公司

At WinLux Biomedicine Technology Co., Ltd., a subsidiary of Chainwin Agriculture and Animal Technology Global Business Group, we strive to set the standard for quality, safety, and value in the discovery, research, and development in the healthcare industry. Our aim includes establishing diseases database, multiplex diagnostic platform, and devoting in new drug development. Throughout our work, WinLux is committed to being transparent, acting with integrity, protecting the environment, and respecting human rights.

Led by the Chairman Chen, Jin-Cai, WinLux reveals its core values from the basis of everything we do: Account-ability, Innovation, Quality Foremost, and Life Respect. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we shall keep accomplishing ultimate goals, "to make a difference for all who rely on us."



Contact us

Chairman: Dennis Chen
Contact Person: Chienwan Lin

· +886-2-2799-3333
· chienwan.lin@chainwin-agrotech.com
· http://win-lux.com
· Rm. 616, Bldg. C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei City 11571, Taiwan (R.O.C.)

Smart Healthcare & Precision Medicine

4

Acer Incorporated
宏碁股份有限公司

The Bio-Medical team of Acer Value Lab focuses on the research and development of personalized cancer therapeutic vaccine that will induce immune responses to specifically recognize and destroy tumors in patients. We are currently developing three platforms for personalized neoantigen-based immunotherapy approaches: 1) Artificial Intelligence (AI) model for neoantigen prediction; 2) mRNA-lipid nanoparticle (LNP) system for payload delivery; 3) Immune monitoring platform for analyzing specific T cell subsets and effector functions to identify novel biomarkers of immunotherapy.

Our team is in collaboration with clinical and research institutions as well as technology platforms and we welcome partnerships to engage personalized treatment strategies.



Contact us

Chairman: Jason Chen, Chairman and CEO
Contact Person: Yeats Yeh, Manager

· +886-2-2696-3131 #7514
· Yeats.Yeh@acer.com
· 26F, No. 116, Sec. 1, Xintai 5th Rd., Xizhi, New Taipei City, Taiwan

Bio Preventive Medicine Corp.
新穎生醫股份有限公司

Bio Preventive Medicine Corp. (BPM), a leading company in renal biomarker area, focuses on translating clinically validated and IP-protected (>79 patents) biomarkers into precision diagnostic solutions for unmet clinical needs. The disease area we focus on includes diabetic kidney disease (DKD), renal injury, and oncology.

Human uPTM3-DKD (DNlite-IVD013) ELISA test is a urinary prognosis test for predicting/monitoring risk of kidney disease progression, and is perfect for routine clinical practice in any healthcare institutes and clinical labs. Besides precision management of DKD, it can also be applied for risk assessment of Acute Kidney Disease, and Graft Failure in kidney transplant patients.

Commercially, DNlite-IVD103 is CE-IVD marked, approved by Malaysia MDA, and also launched in Japan and US as RUO kit. Furthermore, several other worldwide regulatory approvals are in preparation. BPM is ISO17025 and ISO13485 accredited, and listed in Taiwan emerging stock market (code: 6810).

Contact us

CEO: Karen Tseng, Ph.D., MBA
Contact Person: Lai, Chi-Ting, Manager

- +886-3-560-1816
- karen.tseng@bpmbiotech.com
- http://www.bpmbiotech.com
- 6F.-1, No.18, Taiyuan St., Zhubei City, Hsinchu County 302, Taiwan

iAnalyzer Inc.
愛思分析儀器股份有限公司

The company was founded in April 2021, with the goal of developing portable analytical instruments to meet the needs of real-time and on-the-spot measurement. In the initial stage, it is expected to be applied to biomedical, food safety, environmental safety, semiconductor, chemical and environmental protection industries. The medium-term development can be applied to customs, postal systems, airports for illegal drugs as well as explosives detection. In the long run, the second generation of products will be mini size similar to a smart phone.

The company's initial main products include handheld ion mobility spectrometer, portable liquid chromatographs, portable mass spectrometers, and portable liquid chromatography mass spectrometers.

The key technologies provide portable and low-cost for the above instruments. The company will keep Taiwan as the R&D center, and establish overseas sales departments to enter the global market.



Contact us

Chairman: Chung Hsuan Chen
Contact Person: Cherry Lin

- 02-2785-5520
- ianalyzerinc@gmail.com
- www.ianalyzer.com.tw
- C324, 3F, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist.,Taipei

Instant NanoBiosensors Co., Ltd.
奈捷生物科技股份有限公司

Instant NanoBiosensors is an innovative life science company which has developed the ultra-sensitive digital immunoassay platform based on patented FOPPR™ (fiber optical particle plasmon resonance) sensing technology and patented IN-Chip (auto-flowing microfluidic chip) technology for the life science research and in vitro diagnostics markets. The simple and ultra-sensitive blood-based biomarker platform that could pinpoint the Alzheimer's disease process well before any cognitive symptoms would allow physicians to give any potential disease-slowing therapy at a very early point in the disease process. Our goal is to offer clinical researchers and physicians testing solutions with higher precision, real-time and convenience to serve as the basis for early detection and disease monitoring. The additional beneficial features provided are portable ease of use and inexpensive sensor chips in a cost-effective manner to light up the hope for early detection of Alzheimer's disease in the future.



Contact us

Chairman: Tony Chung(President & Co-founder)
Contact Person: Suri Huang (Marketing Director)

· +886-2-2653-8655#120
· cmo@instantnano.com
· www.instantnano.com
· Rm.C328, 3rd Floor, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist. Taipei City 115, Taiwan

JUN ZHI Biomedical Co., Ltd.
俊質生醫股份有限公司

JUNZHI is a biotechnology team from Taiwan, and we have established research and development centers and Operations Center in National Biotechnology Research Park and Tainan Science Park respectively. The technologies authorized by many top research and development units, including Academia Sinica, National Tsing Hua University, National Yang-Ming University and Kaohsiung Medical University, etc. After many years of research and development, we developed the cancer screening service targeted on cancer of digestive system.

The technology of SAA MS screening and interpretation of MS spectra come from Academia Sinica. NTHU is responsible for the development of Magnetic Nanoparticles and antibody for extraction and purification of SAA. NYMU and Metal Industries Research & Development Centre help develop the bio-algorithms, making it more accurate. Last but not least, KMU work on clinical trials and the integration of clinical information to ensure that SAA TEST has high accuracy and also help practically in the medical field.

Contact us

Chairman: Ko, Huei-Ju
Contact Person: Lai, Chi-Ting, Manager

· +886-2-2653-8716
· junzhibio@junzhibio.com
· http://www.junzhibio.com/
· Rm. 330, Bldg. C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei City 11571,Taiwan (R.O.C.)

LumiSTAR Biotechnology, Inc.
昱星生物科技股份有限公司

LumiSTAR develops various platforms by packaging bioimaging and iPSC technologies together to make cellular response visualizable in real time. Our designed protein-based indicators with different dynamic ranges allow long-term observation and measurements, as they are non-toxic to the cells. Thus, drug efficacy and toxicity can be studied at early stages to shorten the process of product development.

Applications:

1. iPSC High Content/Throughput Screening Platform:

For Cell Therapy:

- Development of iPSC cell reprogramming and differentiation
- iPSC differentiated cells functional testing platform

For Drug Development:

- Cardiac and neurodegenerative diseases models
- Drug efficacy study
- Toxicity evaluation at early stages
- Support phenotypic screening

2. Pseudovirus High Throughput Imaging Screening Platform

- Pseudovirus construction for various mutant strains
- Neutralizing antibody screening, vaccine validation and drug screening
- Customized service

3. Personalized/Precision Medicine



Contact us

CEO: Yu-Fen Chang, Ph.D.
Contact Person: Chih-Chuan Su, Ph.D

- +886-2-2783-5860
- chih-chuan.su@lumistar.com.tw
- http://www.lumistar.com.tw/
- Rm. C524, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei City 11571, Taiwan

Molsentech
矽基分子電測科技股份有限公司

Molsentech's Semiconductor-based Biosensor leverages ultra-high sensitivity to integrate the electrical charge of biomolecules with the technologies of surface modification and biomolecular detection to develop an assay that can be applied to detect not only RNA but also proteins for a variety of diseases, including COVID-19. Our biosensor assay combines the advantages the velocity of rapid screening and the high accuracy of traditional PCR assays, providing 5-minute testing time with 95% accuracy that makes it the best solution for early detection.

Molecular biosensing real-time analyzer, SENEDIA, is an electrical-based ultra-high sensitivity device capable of catching minimal charge change of electrical current. Compared with optical-based readers, the Semiconductor-based Biosensor powers SENEDIA to be able to detect ultra-low concentration of pathogens from minimal size of a wide range of samples (e.g. blood, saliva, urine, and etc.) to get detection results before symptoms appear, benefiting people's health on the front of disease prevention.

Products	Applications	Phases
Bio-FET Biosensor & Biomolecular Analyzer & Reagent	Covid19 RNA Rapid Test	Received EUA
	Respiratory Infectious Disease Detection	Pre-clinical
	Cancer Detection	Pre-clinical
	Pet Cancer Detection	Coming soon in 2023
	Microorganism Detection	Pre-clinical



Contact us

CEO: Chia-Jung Chu
Contact Person: Sheng-Yuan Fan, Executive Assistant to CEO

- +886-2-2783-5173
- molsentech@molsentech.com
- http://www.molsentech.com
- Rm. 416, Blog. C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei City 115202,Taiwan (R.O.C.)

NanoRay Biotech Co., Ltd.
和鑫生技開發股份有限公司

NanoRay

NanoRay Biotech has stationed in National Biotechnology Research Park since 2020, devoting to the development of characteristic X-ray technology, applying to medical imaging and cancer therapy.

“Auger Molecular Therapy” is a novel cancer therapy technology. Based on the characteristic X-ray generated by the patented transmission type X-ray tube developed by NanoRay Biotech, Auger effect is efficiently induced in specific heavy atom that release enormous energy in nano-scale space of cancer DNA, inducing aggressive DNA damage and cancer cell death, while lowering the radiation dose received by normal tissues.

Auger Moleculer Therapy has been approved for IND by US FDA. A phase 1 clinical trial will be administrated in 2023.



Contact us

Chairman: Maick Su
Contact Person: Yi-Hsien Lin

· 02-2796-8909
· jessyca@nanoray.com
· https://nanoray.com/
· 7F., No.91, Xinhu 1st Rd., Neihu Dist., Taipei City 114

Nebulum Technologies
諾倫科技股份有限公司

NEBULUM

Nebulum 3D Pathology Platform offers a one-stop solution for therapeutic approach optimization. We provide a universal, multi-dimensional visual analytic solution for scientists, clinical researchers and diagnosis professionals. This offers access and insights on biology studies, neuroscience research and pharmaceutical research for clinical diagnosis. Our 3D Whole Tissue Imagine Service will accelerate our client’s research.

We offer a one-stop sample-to-data solution platform. With our proprietary tissue clearing, immunolabeling, lightsheet imaging and data processing technologies, our clients can gain access to the most up-to-date solutions and integrate the best available 3D tissue data into their research.



Contact us

CEO: Billy Huang
Contact Person: Wayne Chiang, Chief Business Officer

· +886-2-7752-3723 #301
· info@nebulumtech.com
· https://nebulumtech.com/
· Rm. 420, Bldg. C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei City 11571, Taiwan (R.O.C.)

SYNCELL Inc.
新析生物科技股份有限公司

SYNCELL is building a novel spatial biology system, Microscoop™, the world's first in-cell "pickable" high-content microscope-based platform. The system leverages AI-based pattern-recognition algorithm to selectively harvest proteins and nucleic acids in situ from user-defined areas of interest. Using our proprietary subcellular photosensitive labeling reagents, the instrument can effectively "tag" and isolate both known and novel targets for a wide range of cell and tissue biology applications. It is uniquely suited for spatial proteomics and offers distinct capability for discovering novel protein expression to overcome the limitation of all current spatial proteomics systems that can only study known proteins. The system also has the potential to generate multi-omics data on the same cell or tissue sample to delineate new insights on novel biomarker functions that cannot be explored by current technologies.



Contact us

Founder & CEO: Jung-Chi Liao
Contact Person: Jung-Chi Liao

· +886-2-2785-6780
· jcliao@syncell.com
· https://syncell.com/ourteam/
· Rm. 502/503, Bldg. C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei City 11571, Taiwan (R.O.C.)

VITAE Biomedical Co. Ltd.
微體生物醫學股份有限公司

VITAE Biomedical Co. Ltd. is an innovative screening technology company, providing valuable screening technologies for cancers and other diseases. We hold patents in multiple countries and seek to apply the results of our research to medical communities worldwide.

In response to the highly unmet needs for lung cancer screening, our featured reagent kits target a biomarker specific for lung cancer screening in patients' urine. Our breakthrough method is non-invasive, non-radiative, and made possible for early diagnosis. This technology provides excellent benefit-to-risk ratio to the public, serving the needs for frequent monitoring of high-risk individuals and lung cancer patients, and fulfilling a key screening element in regular health checks.

We are committed to continuously deliver our capabilities and services to the people, developing the most needed screening tools that enable accurate and speedy diagnosis with the hope of improving survival rates and life quality of patients.

Contact us

General Manager: Lee, I-Shu, Ph.D.
Contact Person: Hsin-Ying Chang, CFA, Special Assistant

· +886-2-2697-6509
· service@vitae.com.tw
· https://vitae.com.tw
· Rm. 614, Bldg. C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei City 11571, Taiwan (R.O.C.)

Investment Opportunities

NBRP BioHub Taiwan

Resident Companies in Shared Space

INVESTMENT OPPORTUNITIES

RESIDENT COMPANIES IN SHARED SPACE

AIBIOS K.K.
日商艾栢生技股份有限公司

We believe by using our unique knowledge can improve people's lives, and for the benefit of society, the economy, and the environment. With a strong passion, our founder and CEO Akio Sato found the company in 2015 Tokyo, Japan.
We're a group of people with passion, focus on create solutions that help people live healthier lives.
Today, our team in Japan, Taiwan, and United States, focuses on discovering and delivering transformational medicines and products in several key therapeutic areas including immunology, oncology, and neuroscience through our growing pipeline. Each day, we work to deliver sustainable solutions that improve the health of our business and the health of humankind.

Contact us

CEO: Akio Sato
Taiwan Business Office Representative:
Shizue Sato, Director, Management Department.
Contact Person: Dr. Yow-Sien Lin, Senior Director, R&D Department.

- +886-2-7756-6236
- yowsien.lin@aibios.com
- https://www.aibios.com/
- 9F,No.156,Sec 3,Minsheng E. Rd.,Songshan Dist., Taipei City 10596, Taiwan (R.O.C.)

Apexcella Biomedical Inc.
艾沛生醫股份有限公司

Apexcella Biomedical Inc. has developed unique three-stage apexNK cell expansion technology, which can produce mass apexNK cells with high purity and high cytotoxicity. Based on the technology, we are committed to develop the autologous or allogeneic apexNK cell therapies, which can provide cancer patients the next-generation, novel and effective or curative therapies.

Contact us

CEO: Dr. Chi-Feng Chang
Contact Person: Dr. Jen-Chine Wu, CTO

- +886-2-7756-0756
- service@apexcella.com
- A615, No.99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei, 11571, Taiwan

LuminX Biotech Co., Ltd.
路明思生技股份有限公司

LuminX Biotech dedicates to accelerate the optimization of cell-therapy-products through specific understanding of therapeutic cells distribution in-vivo, long-term viability, as well as their biological fate either in preclinical or clinical setting and our technologies can transition a potential therapy from the research stage to advanced clinical and commercial applications to save lives.

Contact us

CEO: Long-Jyun Su
Contact Person: Long-Jyun Su

- +886-0972-622756
- harrysu@luminxbiotech.com
- www.luminxbiotech.com
- 115 F17, No.3, Park St.Nangang Dist., Taipei, Taiwan

Ochre Bio Taiwan Ltd.
赭石生醫有限公司

Ochre Bio, HQ'd in Oxford UK, develops genomic medicines that rejuvenate transplanted livers, ultimately with the goal of applying these therapies to treat fatty liver disease (NASH/NAFL) and other metabolic diseases. Ochre Bio Taiwan is Ochre's first overseas research site, focusing on Target Discovery and Target Validation. The site will employ single-cell and spatial sequencing, advanced genomics, and high-throughput screening to identify disease-causing genes, and develop combination therapies together with Oxford HQ. In Jan 2021, Ochre Bio completed the largest genomic atlas of the liver, and is currently progressing multiple GalNAc-siRNA candidates toward the clinic.

Contact us

Director, Taipei Research: Tess T.H. Lu, Ph.D.
Contact Person: Tess Lu, Ph.D.

- +886-2-2653-8673 #2031
- tesslu@ochre-bio.com
- https://www.ochre-bio.com
- Rm. 403, Bldg. C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei City 11571, Taiwan (R.O.C.)

Pharmasaga Co. Ltd.
藥祇生醫股份有限公司

Pharmasaga is an Academia Sinica-derived biotech company, and focus on the development of a first-in-class diabetes drug, PS-001. PS-001 is an inhibitor of Pdia4 protein, which plays a critical role in diabetes development. Oral administration of PS-001 in diabetic mice can prevent the beta cell death through ROS decreasing, stabilize the blood sugar and reverse diabetes. The preclinical studies and CMC had been completed. The US IND of PS-001 had been approved, and the Phase I clinical trial will be launched.

Contact us

Chairman: Sonya Wu
Contact Person: Tab Chen

- +886-0975-163-411
- contact@pharmasaga.com
- http://www.pharmasaga.com/
- C311, No. 99, Lane 130, Sec. 1, Academia Road, Taipei, Taiwan

Zenith BioDesign Lab Co., Ltd.
禹智生物科技股份有限公司

Zenith BioDesign Lab(ZBL) has positioned itself upstream of the drug development industry chain through our antibody drug design platform technology and full-range capabilities for R&D. ZBL expects to facilitate drug development by combining the process and production strengths of CMOs or CDMOs in the biopharmaceutical industry. Synergistic collaborations built on our own patented ZBL-UmaskAb technology is one of our win-win business strategies.

Contact us

Chairman: Huang, Huei-Luen Ph.D Founder & CTO
Contact Person: Lai, Kuei-Tai Ph.D. Founder & CSO

- +886-93201-6092
- laikt@zbiodesign.com
- Rm. 303, Bldg A, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei City 11571 , Taiwan (R.O.C.)

Topmunnity Therapeutics Taiwan Limited
得勝醫學科技股份有限公司

Topmunnity Therapeutics Taiwan Ltd., established in 2019, hope to improve the efficiency and precision of drug treatment through innovative cancer therapy, and meet the needs of cancer patients who still lack effective treatment. Topmunnity focuses on the research and application of immunotherapy and hope to help prolong and improve the quality of patient's life.

The CAR-108 developed by Topmunnitiy is the CAR-T cell therapy (Chimeric antigen receptor T cells) , the scFv can accurately identify glycosylated antigen on the tumors, the indication will be treating the solid tumors. In the cell-based experiments, It has been proven that CAR-108 can kill 80% of tumor cells effectively. In the in vivo animal study, the tumor was totally remission after the CAR-T treatment.

Contact us

Chairman: Amy Huang CEO

- +886-2-23912180
- info@topmunnity.com
- https://zh.topmunnity.com/contact
- Rm. 403, Building C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei City 115202 , Taiwan (R.O.C.)

Biomedical Ecosystem Resources

NBRP BioHub Taiwan

BioHub Taiwan Accelerator

INVESTMENT OPPORTUNITIES FROM

BIOHUB TAIWAN ACCELERATOR

National Biotechnology Research Park 國家生技研究園區

BioTReC 生醫轉譯研究中心 Biomedical Translation Research Center

BioHUB TAIWAN

Baker McKenzie
國際通商法律事務所

We provide full range of legal services to local and foreign clients. As part of Baker McKenzie's global network of firms, we also deliver seamless legal service that is both global and local. With nearly 100 legal services professionals , including lawyers and patent engineers, the credentials of Baker McKenzie's lawyers in Taiwan speak for themselves.

Contact us

Contact Person: Hao-Ray Hu (Executive Partner)

- +886-2-2715-7281
- hao-ray.hu@bakermckenzie.com
- https://www.bakermckenzie.com.tw/zh-hant

Farmar International Patent and Trademark Offices
法瑪國際專利商標事務所

Famar International Patent and Trademark Offices integrates Famar Licensing Co., Ltd. to provide one-stop service. Except patent prosecution and trademark registration, Farmar provides professional services such as intellectual property management, technology authorization, technology evaluation and business model advice; assisting startup companies to establish their business mechanism. The clients we served include California Institute of Technology, Illumina, National Health Research Institutes, National Taiwan University, National Yang Ming Chiao Tung University, National Chung Hsing University, National Cheng Kung University, China Medical University, Council of Agriculture, Taipei and Taichung Veterans General Hospital, Yungshin Pharm Ind. Co. Ltd, Taiwan Advance Bio-Pharmaceutical Incorporation...etc. Our professional team is divided into two groups: the biochemical group (biotechnology, medicine, chemicals, materials, medical engineering) and the electromechanical group (electrical, electronics, semiconductor, optoelectronics, communications, machinery, general application items). The team is composed of experts with the experience of patent examination in Taiwan Intellectual Property Office and qualification as US or Taiwan patent attorney.

Contact us

Contact Person: Fu Miao Tsai (Manager)

- +886-2-2507-3191
- tai@farmar.com.tw
- http://www.farmar.com.tw/index.php

Global Bio & Investment
環球生技雜誌

GeneOnline is a leading biotech media and market intelligence platform offering in-depth healthcare and biopharma insights. Our Mission is to provide the latest global biotech/pharma trends covering exclusive KOL interviews, market updates, emerging technologies and more. We are the go-to option for any company seeking global exposure and partners in the biopharma sector.

Contact us

Contact Person: Emma Lin (Digital Content Director)

- +886-2-27261065 ext.13
- emma.lin@gbimonthly.com
- https://www.gbimonthly.com

GeneOnline US Inc

GeneOnline is a leading biotech media and market intelligence platform offering in-depth healthcare and biopharma insights. Our Mission is to provide the latest global biotech/pharma trends covering exclusive KOL interviews, market updates, emerging technologies and more. We are the go-to option for any company seeking global exposure and partners in the biopharma sector.

Contact us

Contact Person: Ling Chen (HR / Admin Officer)

- +886-2-2514-0370
- ling.chen@geneonlineasia.com
- https://www.geneonline.com/

Grant Thornton Taiwan
正大聯合會計師事務所

Grant Thornton Taiwan was founded in 1971. We are an ISO certified firm and have approximately 250 employees in Taiwan.We serve dynamic, growing companies that are on the move because we too are a dynamic, growing firm on the move. Having started out as a small practice in Taipei in 1971, we now have offices in Hsinchu, Taichung, and Kaohsiung, which provide geographic coverage that can meet the needs of most companies doing business in Taiwan. We understand the needs and aspirations of growing companies on a personal level, and we have over 50 years' experience helping companies achieve these aspirations. We measure client satisfaction on an annual basis as part of our ISO certification program. Grant Thornton Taiwan clients continuously rank as highly satisfied. This is partly thanks to our business structure, which is designed to react quickly to our clients' needs. At Grant Thornton Taiwan, we are empowered to make decisions locally, rather than having to move issues up through a complex chain of command. This allows us to consistently provide clients with solutions tailor-made to their circumstances and time restrictions. Grant Thornton Taiwan is structured to provide services to clients via different service divisions. Our service divisions include: Assurance, Bookkeeping, Corporate Finance, Company Registration/Liquidation, Legal Support Service, Payroll, Taxation, Transfer Pricing. Working with Grant Thornton Taiwan, you will feel safe in the knowledge that help and advice on the issues that inevitably arise in a complex regulatory environment are only a phone call away.

Contact us

Contact Person: Rola Wang (Consultant)

- +886-982585839
- rolaw.wang@tw.gt.com
- https://www.grantthornton.tw/

IBMI / RBMP
生策會 / 生策中心

Founded by the former president of the Legislative Yuan of Taiwan, Mr Jin-Pyng Wang, IBMI is an independent, not-for-profit organization voicing Taiwan-based health care industry, promoting interdisciplinary collaborations through its global platform, and creating policy dialogues between public and private sectors. On top of that, IBMI is also a trusted awarding and certification body to health care providers and an incubator to health care startups in areas of novel technologies, services and innovations.

Contact us

Contact Person: Esther Yang

- +886-2-26557888*617
- esther@rbmp.org.tw
- https://ibmi.taiwan-healthcare.org

Pacific 8 Ventures

At Pacific 8 Ventures, we invest at the intersection of breakthrough technology platforms and Biology & Medicine. The team has a unique combination of venture capital, tech platforms, clinical medicine, biomedical engineering, and operational expertise. Through our support, we look to help build great companies that advance human health and well-being.

Contact us

Contact Person: Ser-Chen Fu (Partner)

- +886-933613123
- sfu@pac8.com
- www.pac8.com

Roche Products Ltd.
羅氏大藥廠

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics, as well as growing capabilities in the area of data-driven medical insights help Roche deliver truly personalized healthcare. Roche is working with partners across the healthcare sector to provide the best care for each person.

Contact us

Contact Person: Jack Wang (IT BP)

- +886-972725369
- jack.wang@roche.com
- www.roche.com.tw

Taiwania Capital
台杉投資

Taiwania Capital is a venture capital firm that was founded in August 2017 by the National Development Fund of the Executive Yuan of Taiwan and private enterprises. Our mission is to establish a partnership with companies worldwide and boost Taiwan's economic growth.

We invest in different stages of companies mainly in the tech and biotech fields. By linking technology and capital, Taiwania Capital aspires to also create a robust ecosystem in Taiwan that is rooted in entrepreneurial innovation.

Contact us

Contact Person: Angela Li / Sylvia Lin

- +886-2-27209898 #163；#162
- ali@taiwaniacapital.com; slin@taiwaniacapital.com
- https://www.taiwaniacapital.com/

Tiger Accelerator
台荷加速器

Based in Taiwan & the Netherlands, Tiger Accelerator serves as a bridge between entrepreneurship ecosystems in Asia and Europe. We've been facilitating valuable connections between startups, SMEs, corporates, investors, accelerators, incubators and public stakeholders in the two continents.

With our expertise and network in the two geographies, we link Asian and European innovators with the business resources they need for international expansion, support their international growth ambitions, as well as minimize the uncertainties and risks involved for entrepreneurs to enter unfamiliar markets.

Contact us

Contact Person: Yulia Shi

- +886-905513200
- yulia.shi@tigeraccelerator.com
- https://www.tigeraccelerator.com/

Taiwan Research-based Biopharmaceutical Manufacturers Association (TRPMA)
台灣研發型生技新藥發展協會

TRPMA, established in 2012, is an industry association representing 56 Taiwanese R&D-based biopharmaceutical companies. Our mission is to build up a competitive bio pharma industry in Taiwan by consolidating public and private resources and facilitating product and business development. On behalf of Taiwan bioindustry, TRPMA serves as a window for promoting international partnership in the area of new drugs, vaccines, regenerative medicines and digital medical techs. We welcome your visit!

Contact us

Contact Person: Vian Yeh (Director)

- +886-2-27831262
- trpma@trpma.org.tw
- https://trpma.org.tw/

Taiwan Bio Industry Organization
台灣生物產業發展協會

Since its founding in 1989, the Taiwan Bio Industry Organization (Taiwan BIO) has been promoting the interests of its members from industry, the government and academia as well as promoting the development of the biomedical industries and their contribution to Taiwan's economy and people. The more than 100 organizations and 3,000 individuals that make up Taiwan BIO membership represent the entire life sciences industry spectrum, including from the biotechnology, pharmaceutical, diagnostics, medical devices and materials, agricultural biotechnology, and nutraceuticals sectors.

Contact us

Contact Person: Mia

- +886-2-27836028
- mia@taiwanbio.org.tw
- https://taiwanbio.org.tw/en/